Literature DB >> 18646118

Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification.

Laura Amato1, Silvia Minozzi, Marina Davoli, Simona Vecchi, Marica Mf Ferri, Soraya Mayet.   

Abstract

BACKGROUND: Different pharmacological approaches aimed at opioid detoxification are effective. Nevertheless a majority of patients relapse to heroin use, and relapses are a substantial problem in the rehabilitation of heroin users. Some studies have suggested that the sorts of symptoms which are most distressing to addicts during detoxification are psychological rather than physiological symptoms associated with the withdrawal syndrome.
OBJECTIVES: To evaluate the effectiveness of any psychosocial plus any pharmacological interventions versus any pharmacological alone for opioid detoxification, in helping patients to complete the treatment, reduce the use of substances and improve health and social status. SEARCH STRATEGY: We searched the Cochrane Drugs and Alcohol Group trials register (27 February 2008). Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2008), PUBMED (1996 to February 2008); EMBASE (January 1980 to February 2008); CINAHL (January 2003-February 2008); PsycINFO (1985 to April 2003) and reference list of articles. SELECTION CRITERIA: Randomised controlled trials which focus on any psychosocial associated with any pharmacological intervention aimed at opioid detoxification. People less than 18 years of age and pregnant women were excluded. DATA COLLECTION AND ANALYSIS: Three reviewers independently assessed trials quality and extracted data. MAIN
RESULTS: Nine studies involving people were included. These studies considered five different psychosocial interventions and two substitution detoxification treatments: Methadone and Buprenorphine. The results show promising benefit from adding any psychosocial treatment to any substitution detoxification treatment in terms of completion of treatment relative risk (RR) 1.68 (95% confidence interval (CI) 1.11 to 2.55), use of opiate RR 0.82 (95% CI 0.71 to 0.93), results at follow-up RR 2.43 (95% CI 1.61 to 3.66), and compliance RR 0.48 (95% CI 0.38 to 0.59). AUTHORS'
CONCLUSIONS: Psychosocial treatments offered in addition to pharmacological detoxification treatments are effective in terms of completion of treatment, use of opiate, results at follow-up and compliance. Although a treatment, like detoxification, that exclusively attenuates the severity of opiate withdrawal symptoms can be at best partially effective for a chronic relapsing disorder like opiate dependence, this type of treatment is an essential step prior to longer-term drug-free treatment and it is desirable to develop adjunct psychosocial approaches that might make detoxification more effective. Limitations to this review are imposed by the heterogeneity of the assessment of outcomes. Because of lack of detailed information no meta analysis could be performed to analyse the results related to several outcomes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18646118     DOI: 10.1002/14651858.CD005031.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  15 in total

1.  Improving healthcare for incarcerated women.

Authors:  Sandra A Springer
Journal:  J Womens Health (Larchmt)       Date:  2010-01       Impact factor: 2.681

Review 2.  Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal.

Authors:  Linda Gowing; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

3.  Clinical risk factors for death after release from prison in Washington State: a nested case-control study.

Authors:  Ingrid A Binswanger; Marc F Stern; Traci E Yamashita; Shane R Mueller; Travis P Baggett; Patrick J Blatchford
Journal:  Addiction       Date:  2016-03       Impact factor: 6.526

4.  Predictors of outcome after short-term stabilization with buprenorphine.

Authors:  Maureen Hillhouse; Catherine P Canamar; Walter Ling
Journal:  J Subst Abuse Treat       Date:  2012-09-26

5.  Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community - a potential conduit to improved HIV treatment outcomes.

Authors:  Ali Shabahang Saber-Tehrani; Sandra A Springer; Jingjun Qiu; Maua Herme; Jeffrey Wickersham; Frederick L Altice
Journal:  Contemp Clin Trials       Date:  2011-11-12       Impact factor: 2.226

Review 6.  Buprenorphine for managing opioid withdrawal.

Authors:  Linda Gowing; Robert Ali; Jason M White; Dalitso Mbewe
Journal:  Cochrane Database Syst Rev       Date:  2017-02-21

7.  Defining and Predicting Opioid and Cocaine Treatment Response.

Authors:  Robert A Gardner; David H Epstein; Kenzie L Preston; Karran A Phillips
Journal:  Subst Use Misuse       Date:  2019-07-18       Impact factor: 2.164

Review 8.  Dependence on Prescription Opioids.

Authors:  Johannes Just; Martin Mücke; Markus Bleckwenn
Journal:  Dtsch Arztebl Int       Date:  2016-04-01       Impact factor: 5.594

Review 9.  Alpha₂-adrenergic agonists for the management of opioid withdrawal.

Authors:  Linda Gowing; Michael Farrell; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2016-05-03

Review 10.  Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions.

Authors:  Mishka Terplan; Shaalini Ramanadhan; Abigail Locke; Nyaradzo Longinaker; Steve Lui
Journal:  Cochrane Database Syst Rev       Date:  2015-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.